AVEO Pharmaceuticals (NASDAQ:AVEO) Rating Reiterated by B. Riley

AVEO Pharmaceuticals (NASDAQ:AVEO)‘s stock had its “neutral” rating reissued by analysts at B. Riley in a research report issued to clients and investors on Monday, February 4th, MarketBeat Ratings reports. They presently have a $1.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $5.00. B. Riley’s price objective points to a potential upside of 75.72% from the company’s current price. B. Riley also issued estimates for AVEO Pharmaceuticals’ Q4 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.25) EPS, Q1 2019 earnings at ($0.05) EPS, Q2 2019 earnings at ($0.05) EPS, Q3 2019 earnings at ($0.04) EPS, Q4 2019 earnings at ($0.04) EPS, FY2019 earnings at ($0.17) EPS, FY2020 earnings at ($0.10) EPS, FY2021 earnings at ($0.02) EPS, FY2022 earnings at ($0.04) EPS and FY2023 earnings at $0.20 EPS.

A number of other research analysts have also recently weighed in on AVEO. BidaskClub cut shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 19th. HC Wainwright set a $7.00 target price on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. Zacks Investment Research cut shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. National Securities cut shares of AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 6th. Finally, FBR & Co set a $3.00 target price on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 20th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $2.21.

Shares of AVEO traded up $0.03 during mid-day trading on Monday, reaching $0.57. 3,396,687 shares of the company’s stock were exchanged, compared to its average volume of 6,744,609. AVEO Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $3.59. The stock has a market cap of $78.34 million, a price-to-earnings ratio of -3.56 and a beta of 1.26.

In other AVEO Pharmaceuticals news, major shareholder Peter W. Sonsini bought 27,300 shares of AVEO Pharmaceuticals stock in a transaction that occurred on Thursday, December 6th. The shares were acquired at an average price of $1.99 per share, for a total transaction of $54,327.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Equity Opportunities Iv Growth bought 170,400 shares of AVEO Pharmaceuticals stock in a transaction that occurred on Monday, December 10th. The shares were acquired at an average price of $1.99 per share, for a total transaction of $339,096.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 697,700 shares of company stock worth $1,168,423 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in AVEO Pharmaceuticals by 2.1% in the 3rd quarter. BlackRock Inc. now owns 7,120,894 shares of the biopharmaceutical company’s stock worth $23,570,000 after buying an additional 143,148 shares in the last quarter. NEA Management Company LLC increased its position in shares of AVEO Pharmaceuticals by 5.1% in the 3rd quarter. NEA Management Company LLC now owns 18,698,038 shares of the biopharmaceutical company’s stock worth $61,891,000 after purchasing an additional 914,316 shares during the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of AVEO Pharmaceuticals in the 3rd quarter worth about $275,000. Hikari Power Ltd bought a new stake in shares of AVEO Pharmaceuticals in the 4th quarter worth about $128,000. Finally, Teachers Advisors LLC increased its position in shares of AVEO Pharmaceuticals by 75.8% in the 3rd quarter. Teachers Advisors LLC now owns 227,334 shares of the biopharmaceutical company’s stock worth $752,000 after purchasing an additional 98,009 shares during the last quarter. Hedge funds and other institutional investors own 42.06% of the company’s stock.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: Why Dividend Stocks May Be Right for You

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.